Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Birkmayer

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
Journal of Neural Transmission|January 1, 1975
Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings)W Birkmayer, P Riederer
Wiener Klinische Wochenschrift|January 5, 2002
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961W Birkmayer, O Hornykiewicz
Munchener Medizinische Wochenschrift (1950)|March 12, 1971
[Verification of gerontotherapeutic effects. (Clinical experimental study on Kavaform)]W Birkmayer, H Rosmanith
Archiv Fur Psychiatrie Und Nervenkrankheiten|January 1, 1970
[Disturbance of tyrosine and tryptophane metabolism in depression]W Birkmayer, W Linauer
Psychopathology|January 1, 1986
Biological aspects of depression in Parkinson's diseaseW Birkmayer, P Riederer
Der Nervenarzt|February 1, 1972
[L-tryptophan therapy of DOPA psychoses]W Birkmayer, E Neumayer
Zeitschrift Fur Neurologie|January 1, 1972
[Modern treatment of parkinsonism]W Birkmayer, E Neumayer
Advances in Neurology|January 1, 1984
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's diseaseW Birkmayer, P Riederer
Internationale Zeitschrift Fur Klinische Pharmakologie, Therapie, Und Toxikologie. International Journal of Clinical Pharmacology, Therapy, and Toxicology|May 1, 1970
[Possibility for assay of psychopharmacological drugs in the example of caffeine and caffeine-free coffee]L Ambrozi, W Birkmayer
Parkinsonism & Related Disorders|July 2, 2008
The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonismW Birkmayer, O Hornykiewicz
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
Journal of Neural Transmission|January 1, 1975
Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings)W Birkmayer, P Riederer
Wiener Klinische Wochenschrift|January 5, 2002
The effect of l-3,4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism. 1961W Birkmayer, O Hornykiewicz
Munchener Medizinische Wochenschrift (1950)|March 12, 1971
[Verification of gerontotherapeutic effects. (Clinical experimental study on Kavaform)]W Birkmayer, H Rosmanith
Archiv Fur Psychiatrie Und Nervenkrankheiten|January 1, 1970
[Disturbance of tyrosine and tryptophane metabolism in depression]W Birkmayer, W Linauer
Psychopathology|January 1, 1986
Biological aspects of depression in Parkinson's diseaseW Birkmayer, P Riederer
Der Nervenarzt|February 1, 1972
[L-tryptophan therapy of DOPA psychoses]W Birkmayer, E Neumayer
Zeitschrift Fur Neurologie|January 1, 1972
[Modern treatment of parkinsonism]W Birkmayer, E Neumayer
Advances in Neurology|January 1, 1984
Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's diseaseW Birkmayer, P Riederer
Internationale Zeitschrift Fur Klinische Pharmakologie, Therapie, Und Toxikologie. International Journal of Clinical Pharmacology, Therapy, and Toxicology|May 1, 1970
[Possibility for assay of psychopharmacological drugs in the example of caffeine and caffeine-free coffee]L Ambrozi, W Birkmayer
Parkinsonism & Related Disorders|July 2, 2008
The effect of l-3,4-dihydroxyphenylalanine (=DOPA) on akinesia in parkinsonismW Birkmayer, O Hornykiewicz
Pageof 8